Genmab — Februar 2018
-
Jeg er meget spændt på hvad Winkel har at sige om D-VMp's muligheder i US. Ækvivalenten derovre til VMp er CyborD. Vi skulle få fronline data her i februar fra et fase 2 studie netop i D+CyborD. Det er ganske vist kun et enarmet fase 2 studie, men det måler kun på effektiviteten. Gode data herfra kunne få US-læger til at overveje D+CyborD - ikke mindst på baggrund af Alcyone også.
-
Interessant nok kører D+CyborD-studiet kun med US-lokationer med Estimated Primary Completion Date : February 20, 2018 https://www.clinicaltrials.gov/ct2/show/study/NCT02951819?term=daratumumab+cybord&rank=3&show_locs=Y#locn
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind